Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC
Status:
Recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
The primary hypothesis is that camrelizumab in combination with pemetrexed/ carboplatin will
present a better efficacy for treatment of first line metastatic non-squamous non-small cell
lung cancer and minimize the risk of toxicity